STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit
STAT spoke with the global head of Boehringer Ingelheim's innovation unit, about work BI is known for and not as well known for. Another topic: the Inflation Reduction Act.
LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.
There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.
In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.
What's Your Reaction?
